Results 211 to 220 of about 134,000 (307)

A Pharmacogenomics‐Guided Antihypertensive Strategy for Blood Pressure Reduction in Rural China: A Cluster‐Randomized Controlled Trial

open access: yesHealth Care Science, EarlyView.
This manuscript reports the findings from the Pharmacogenomic‐guided Antihypertensive Strategy Trial study amidst the deteriorating blood pressure control observed globally during the COVID‐19 pandemic. A pharmacogenomics‐guided strategy achieved a 98.4% blood pressure control rate at 4 weeks in rural China.
Wangjun Qin   +22 more
wiley   +1 more source

The angiotensin II type 1 receptor blocker valsartan in the battle against COVID-19. [PDF]

open access: yesObesity (Silver Spring), 2021
de Ligt M   +5 more
europepmc   +1 more source

Association between Angiotensin II Type 1 Receptor Gene Polymorphism and Essential Hypertension: the Ohasama Study

open access: bronze, 2004
Ken Sugimoto   +9 more
openalex   +2 more sources

The angiotensin II type 1 receptor blocker azilsartan can overwhelm the sympathetic nerve activation stimulated by coadministration of calcium channel blockers [PDF]

open access: hybrid, 2019
Michio Fukuda   +9 more
openalex   +1 more source

Nephrological perspectives on the underutilization of SGLT2is in heart failure and chronic kidney disease

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 1490-1491, April 2025.
Özant Helvacı   +4 more
wiley   +1 more source

Cardiovascular disease incidence and cancer risk in two large European prospective cohorts

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Cardiovascular disease (CVD) and cancer share risk factors and biological mechanisms, raising questions about potential associations between the two, particularly regarding CVD duration and cancer onset. Whether CVD influences subsequent cancer risk, however, remains inconclusive.
Emma Fontvieille   +25 more
wiley   +1 more source

Home - About - Disclaimer - Privacy